ClinicalTrials.gg
Enrolling by invitationNCT03167203Updated Jul 13, 2026

A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy

A Phase 1/2 interventional study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degenerative Disease, sponsored by Astellas Institute for Regenerative Medicine. Enrolling by invitation at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Astellas Institute for Regenerative Medicine (part of Astellas Pharma Inc) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to is to evaluate the occurrence of late onset (i.e., greater than 5 years after treatment) adverse events of special interest (AESI) in participants who have received sub-retinal transplant of human embryonic stem cell derived - retinal pigment epithelial (hESC-RPE) cells in an AIRM-sponsored clinical trial. The events of special interest are adverse events (AEs) that are presumed to have a potential causal relationship to the hESC-RPE cells.

Read the detailed description

Participants will be contacted by the Patient Outreach Center (POC) on an annual basis to complete a questionnaire about the occurrence of AESI, as defined in the Outcome Measure section.

The questionnaire will be completed directly by the participant (via a secure web based platform) or will be administered via telephone by a POC staff member. In the event of the occurrence of a AESI, study participant will be encouraged to contact the POC as soon as possible, rather than wait for the annual questionnaire completion. Follow up data is inclusive of the 1 year in the core trial, 4 years in the long term follow up trial and 10 years in this long term safety follow up. Participation for United Kingdom participants will be life-long.

02

Conditions studied

  • Macular Degenerative Disease

Keywords

  • hESC-RPE
  • Macular Degenerative Disease
03

In context

Lead sponsor

Astellas Institute for Regenerative Medicine is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

First submitted after Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant was treated with hESC-RPE cell therapy in an Astellas Institute for Regenerative Medicine (AIRM) sponsored clinical trial in macular degenerative disease.
  • Participant is able to understand.

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    hESC-RPE cells

    Participants previously enrolled into an Astellas Institute for Regenerative Medicine (AIRM) sponsored clinical trial and treated with Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial (hESC-RPE) cells

    Biological: Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

Interventions

  • BiologicalHuman Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

    Participants who have received sub-retinal transplant of hESC-RPE cells in an AIRM sponsored clinical trial

    Also known as: ASP7316

06

What researchers measure

Primary outcomes

  1. Number of adverse events (AEs) that are ophthalmologic, neurologic, infectious or hematologic

    Adverse events (AEs) will be coded using Medical Dictionary for Regulatory Activities (MedDRA). Participant self-reported via an annual questionnaire of adverse events that are ophthalmologic, neurologic, infectious or hematologic.

    Time frame: Up to 15 Years

  2. Number of new diagnoses of an immune-mediated disorder

    Any new diagnosis of an immune-mediated disorder will be participant self-reported via an annual questionnaire.

    Time frame: Up to 15 Years

  3. Incidents of new cancer, irrespective of prior history

    Any new cancer, irrespective of prior history, will be participant self-reported via an annual questionnaire.

    Time frame: Up to 15 Years

  4. Incidents of hESC-RPE cell proliferation

    Occurrence of human embryonic stem cell derived - retinal pigment epithelial (hESC-RPE) cell proliferation will be participant self-reported via an annual questionnaire.

    Time frame: Up to 15 Years

  5. Incidents of ectopic tissue (RPE or non-RPE) formation

    Occurrence of ectopic tissue (retinal pigment epithelial \[RPE\] or non-RPE) will be participant self-reported via an annual questionnaire

    Time frame: Up to 15 Years

  6. Number of participant reported pregnancies or pregnancy of participant's partner

    Occurrence of pregnancy will be participant self-reported via an annual questionnaire

    Time frame: Up to 15 Years

  7. Number of reported pregnancy outcome(s)

    Occurrence of pregnancy outcomes will be participant self-reported via an annual questionnaire

    Time frame: Up to 15 Years

  8. All cause death

    All causes of death will be collected via an annual questionnaire (through participant-designated secondary contacts)

    Time frame: Up to 15 Years

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2018 (actual). Primary completion is estimated for Mar 2029, 134 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2017
First posted
May 25, 2017
StartActual
Jan 8, 2018
Primary completionEst.
Mar 31, 2029
CompletionEst.
Mar 31, 2029
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03167203
Responsible party
Sponsor
First posted
May 25, 2017
Start date
Jan 8, 2018
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Jul 13, 2026

Study contacts

Medical Monitor
study director · Astellas Institute for Regenerative Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion